HIV Therapy: Disease Management and Treatment Optimization (HIV renewal requirement)


Program Details

  • Intended Audience: Pharmacists in all practice settings (this CPE is required by the Florida Board of Pharmacy for pharmacist license renewal).
  • Universal Activity Number:  0012-0000-18-084-H02-P
  • Contact Hours: 3.0 Florida Board approved HIV/AIDS renewal requirement
  • Program Fees: $50.00
  • Dates Available: 10/26/2018 to 10/26/2021
  • Activity Type: Knowledge
Enroll Now with Gatorlink Login
Enroll Now with External Login

Summary

Pharmacists can play a critical role in the care of persons living with human immunodeficiency virus (HIV).  This activity will provide an overview of the history, epidemiology, pathophysiology, and viral targets of antiretroviral therapy (ART).  Additionally, the different classes of antiretrovirals will be discussed, including the mechanism of action, common side effects, and limitations or special considerations which are unique to specific agents.  The pharmacist’s role in adherence will be discussed, as well as the treatment of patients, including special populations (e.g., pediatric patients, elderly).

This course is approved by the Florida Board of Pharmacy to fulfill the HIV/AIDS licensure renewal requirements outlined in Rule 64B16-26.103. Credit cannot be awarded toward your general license.  Contact us if with any questions.


Objectives

Module 1: Introduction to HIV

At the completion of this module, the participant will be able to:

  • Define Human Immunodeficiency Virus (HIV) and Acquired Immune Deficiency Syndrome (AIDS)
  • Describe disease epidemiology
  • Recognize modes of transmission including transmission between healthcare workers and patients
  • Describe the HIV life cycle and viral targets of antiretroviral drug therapy
  • Discuss the diagnostic tests used for HIV
  • Recognize laboratory markers used to monitor patient health
  • Describe current treatment recommendations for initiating HIV drug therapy
  • Identify the different classes of ARVs and the mechanism of action of each class: NNRTIs, NRTIs, INSTIs, PIs, CCR5 Antagonists, and Fusion Inhibitors
  • Describe common side effects associated with each class
  • Identify any limitations or special considerations that are unique to particular agents
  • Identify which antiretrovirals are enzyme inducers and inhibitors
  • Recognize food requirements for antiretrovirals whose concentrations may be affected
  • Identify and manage common drug-drug interactions
  • Determine when renal and/or hepatic dose adjustments are appropriate
  • Recognize Brand and Generic formulations, including combination dosage forms
  • Describe different methods for improving medication adherence

Module 2: Integrase Inhibitors and NNRTIs

At the completion of this module, the participant will be able to:

  • Identify the different classes of ARVs and the mechanism of action of each class
  • Describe common side effects (adverse drug reactions) associated with each class
  • Describe common drug-drug interactions of each class
  • Identify any limitations or special considerations that are unique to particular agents

Module 3: Treatment of HIV: the NRTIs

At the completion of this module, the participant will be able to:

  • Describe common side effects associated with each class
  • Identify any limitations or special considerations that are unique to particular agents
  • Identify which antiretrovirals are enzyme inducers and inhibitors
  • Recognize food requirements for antiretrovirals whose concentrations may be affected
  • Identify and manage common drug-drug interactions
  • Determine when renal and/or hepatic dose adjustments are appropriate
  • Recognize Brand and Generic formulations, including combination dosage forms
  • Describe different methods for improving medication adherence
  • Identify the different classes of ARVs and the mechanism of action of each class
  • Describe common side effects (adverse drug reactions) associated with each class

Module 4: HIV Special Populations

At the completion of this module, the participant will be able to:

  • Describe HIV epidemiology, diagnosis, treatment, and adherence assessment in pediatric and adolescent patients
  • Describe strategies for the prevention of transmission of HIV during pregnancy
  • Discuss the epidemiology, risk factors, and treatment of HIV in the elderly
  • Describe HIV treatment challenges in patients with comorbid substance abuse
  • Identify treatment challenges experienced by transgender persons with HIV

Module 5: HIV Florida Law

At the completion of this module, the participant will be able to:

  • Review Florida law as it pertains to HIV testing
  • Discuss Florida law in regards to partner notification

Disclosure Statement

The following speakers, reviewers, and planning committee members have disclosed that he/she has no relevant financial disclosures. No one else in a position to control content has any financial relationships to disclose.

Eric F. Egelund, Pharm.D., Ph.D.
Clinical Assistant Professor
Department of Pharmacotherapy and Translational Research
College of Pharmacy, University of Florida

Priti N. Patel, Pharm.D., BCPS
Clinical Associate Professor/ Assistant Campus Director
College of Pharmacy, University of Florida


Schedule of Activities and Requirements for Successful Course Completion

Review the course material, receive a 70% or higher on post-tests, and submit an online program evaluation.


Credit Reporting

  • The University of Florida College of Pharmacy will report CPE credit to CPE Monitor and CE Broker when applicable. If you would like a paper statement of credit, you may print it from your NABP e-profile.
  • All pharmacists and pharmacy technicians maintain their own license and/or certification and it is their responsibility to follow up with the Office of Continuing Education at the University of Florida if any CE credit discrepancies are found.
  • It is at the University’s discretion to award or deny credit to a late claiming participant (i.e. after 60 days of the participant engaging in a CPE activity) as it is the University’s CE activity and the provider needs to ensure the requirements necessary for credit are successfully completed.
  • The University may request access to CPE Monitor® if the activity in question occurred within the previous 6 months and with an appropriate reason for access, i.e. power outage, etc.

Per the Florida Board of Pharmacy:
If you are renewing your license for the first time AND your initial renewal occurs 12 months or more after initial licensure date, you are required to complete 15 (5 must be live)  general, 2 hour medication errors, 2 controlled substances and 1 hour in HIV/AIDS.

If your initial renewal occurs less than 12 months from your initial licensure date you are required to complete 1 hour in HIV/AIDS, 2 hours of medication errors and 2 hours of controlled substances.


Program Financial Support

This course received no outside funding support.


Computer Requirements

Computer and Internet access are required to complete this course. Course content is provided via Canvas.

The minimum hardware, software, and Internet requirements for Canvas can be found here.


Policies

Refund Policy for CE Courses

Privacy and Confidentiality Policy


Copyright

This course in its entirety is copyrighted by the University of Florida Continuing Pharmacy Education and may not be duplicated or reproduced for any other purpose without specific written permission.

For questions or more information, please contact our office.


ACPE logo

The University of Florida College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharma